Congenital muscular dystrophy. Part II: a review of pathogenesis and therapeutic perspectives.

Abstract

The congenital muscular dystrophies (CMDs) are a group of genetically and clinically heterogeneous hereditary myopathies with preferentially autosomal recessive inheritance, that are characterized by congenital hypotonia, delayed motor development and early onset of progressive muscle weakness associated with dystrophic pattern on muscle biopsy. The clinical course is broadly variable and can comprise the involvement of the brain and eyes. From 1994, a great development in the knowledge of the molecular basis has occurred and the classification of CMDs has to be continuously up dated. In the last number of this journal, we presented the main clinical and diagnostic data concerning the different subtypes of CMD. In this second part of the review, we analyse the main reports from the literature concerning the pathogenesis and the therapeutic perspectives of the most common subtypes of CMD: MDC1A with merosin deficiency, collagen VI related CMDs (Ullrich and Bethlem), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker Warburg syndrome, MDC1C, MDC1D), and rigid spine syndrome, another much rare subtype of CMDs not related with the dystrophin/glycoproteins/extracellular matrix complex.

• Authors: Umbertina Conti Reed
• Journal: Arquivos de neuro-psiquiatria (Arq Neuropsiquiatr) Vol. 67 Issue 2A Pg. 343-62 (Jun 2009) ISSN: 1678-4227 [Electronic] Germany
• PMID: 19547838 (Publication Type: Journal Article, Review)

Topics

• Humans
• Muscular Dystrophies (congenital, therapy)